Capital Fund Management (CFM)’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.81M | Sell |
323,436
-135,886
| -30% | -$2.57M | 0.03% | 843 |
|
|
2026
Q1 | $9.99M | Sell |
459,322
-26,131
| -5% | -$506K | 0.05% | 553 |
|
|
2025
Q4 | $10.4M | Sell |
485,453
-294,601
| -38% | -$6.21M | 0.03% | 807 |
|
|
2025
Q3 | $15M | Buy |
780,054
+265,309
| +52% | +$4.73M | 0.04% | 638 |
|
|
2025
Q2 | $8.8M | Buy |
514,745
+314,608
| +157% | +$13.4M | 0.02% | 828 |
|
|
2025
Q1 | $12.8M | Buy |
200,137
+26,392
| +15% | +$2.78M | 0.04% | 592 |
|
|
2024
Q4 | $21.1M | Sell |
173,745
-30,401
| -15% | -$3.73M | 0.05% | 459 |
|
|
2024
Q3 | $25.5M | Buy |
+204,146
| New | +$28.2M | 0.07% | 375 |
|
|
2024
Q2 | – | Sell |
-39,881
| Closed | -$5.16M | – | 2159 |
|
|
2024
Q1 | $5.16M | Sell |
39,881
-35,815
| -47% | -$4.39M | 0.01% | 1040 |
|
|
2023
Q4 | $7.3M | Buy |
+75,696
| New | +$7.26M | 0.02% | 929 |
|
|
2022
Q3 | – | Sell |
-15,028
| Closed | -$1.13M | – | 1637 |
|
|
2022
Q2 | $1.13M | Sell |
15,028
-20,855
| -58% | -$1.53M | 0.01% | 1035 |
|
|
2022
Q1 | $2.8M | Buy |
35,883
+18,471
| +106% | +$1.41M | 0.02% | 820 |
|
|
2021
Q4 | $1.57M | Buy |
+17,412
| New | +$1.49M | 0.01% | 1130 |
|
|
2020
Q2 | – | Sell |
-9,923
| Closed | -$971K | – | 1524 |
|
|
2020
Q1 | $971K | Sell |
9,923
-2,021
| -17% | -$231K | 0.02% | 796 |
|
|
2019
Q4 | $1.54M | Buy |
+11,944
| New | +$1.21M | 0.01% | 938 |
|
|
2019
Q3 | – | Sell |
-7,405
| Closed | -$875K | – | 1876 |
|
|
2019
Q2 | $1.13M | Buy |
7,405
+5,583
| +306% | +$679K | 0.01% | 981 |
|
|
2019
Q1 | $217K | Buy |
+1,822
| New | +$234K | ﹤0.01% | 1565 |
|
|
2018
Q3 | – | Sell |
-48,040
| Closed | -$6.57M | – | 2246 |
|
|
2018
Q2 | $6.35M | Buy |
48,040
+15,842
| +49% | +$1.49M | 0.03% | 632 |
|
|
2018
Q1 | $2.39M | Sell |
32,198
-38,938
| -55% | -$2.6M | 0.01% | 948 |
|
|
2017
Q4 | $3.96M | Buy |
71,136
+65,738
| +1,218% | +$3.48M | 0.02% | 747 |
|
|
2017
Q3 | $245K | Buy |
+5,398
| New | +$216K | ﹤0.01% | 1384 |
|
|
2017
Q2 | – | Sell |
-223,101
| Closed | -$7.26M | – | 1709 |
|
|
2017
Q1 | $6.6M | Buy |
+223,101
| New | +$6.9M | 0.06% | 381 |
|
|
2016
Q1 | – | Sell |
-56,694
| Closed | -$2.19M | – | 1807 |
|
|
2015
Q4 | $2.19M | Buy |
56,694
+14,707
| +35% | +$477K | 0.02% | 650 |
|
|
2015
Q3 | $1.35M | Buy |
+41,987
| New | +$1.42M | 0.02% | 726 |
|
|
2015
Q2 | – | Sell |
-24,730
| Closed | -$328K | – | 1689 |
|
|
2015
Q1 | $328K | Buy |
+24,730
| New | +$330K | ﹤0.01% | 1193 |
|
|
2014
Q4 | – | Sell |
-27,440
| Closed | -$579K | – | 1785 |
|
|
2014
Q3 | $579K | Buy |
+27,440
| New | +$619K | 0.01% | 1108 |
|
|
2014
Q1 | – | Sell |
-369,536
| Closed | -$7.53M | – | 1937 |
|
|
2013
Q4 | $7.53M | Buy |
369,536
+271,948
| +279% | +$8.08M | 0.09% | 266 |
|
|
2013
Q3 | $4.61M | Buy |
+97,588
| New | +$3.76M | 0.06% | 381 |
|
Other funds holding SRPT
EAM
Capital Fund Management (CFM)'s SRPT Position: Q2 2026 in Review
Capital Fund Management (CFM) reduced its Sarepta Therapeutics (SRPT) stake by 30% in Q2 2026, selling an estimated $2.57M and leaving 323,436 shares worth $5.81M. The position accounts for 0.03% of the portfolio, ranked #843.
Capital Fund Management (CFM) first reported a position in SRPT in Q3 2013 and has held it in 28 quarters since. The position peaked at $25.5M in Q3 2024. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.
- Capital Fund Management (CFM) held 323,436 shares of Sarepta Therapeutics worth $5.81M as of Q2 2026.
- Capital Fund Management (CFM) sold 135,886 Sarepta Therapeutics shares in Q2 2026, an estimated $2.57M.
- Sarepta Therapeutics made up 0.03% of Capital Fund Management (CFM)'s portfolio in Q2 2026, its #843 holding.
- Capital Fund Management (CFM) first reported a position in Sarepta Therapeutics in Q3 2013 and has held it in 28 quarters since.
- Capital Fund Management (CFM)'s Sarepta Therapeutics position peaked at $25.5M in Q3 2024.
- 324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.
Based on Capital Fund Management (CFM)'s 13F filing for Q2 2026, filed 13 Aug 2026.